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This study aims to analyze which determinants predict frailty in general and each
frailty domain (physical, psychological, and social), considering the integral conceptual
model of frailty, and particularly to examine the contribution of medication in this
prediction. A cross-sectional study was designed using a non-probabilistic sample of
252 community-dwelling elderly from three Portuguese cities. Frailty and determinants
of frailty were assessed with the Tilburg Frailty Indicator. The amount and type
of different daily-consumed medication were also examined. Hierarchical regression
analysis were conducted. The mean age of the participants was 79.2 years (±7.3),
and most of them were women (75.8%), widowed (55.6%) and with a low educational
level (0–4 years: 63.9%). In this study, determinants explained 46% of the variance of
total frailty, and 39.8, 25.3, and 27.7% of physical, psychological, and social frailty
respectively. Age, gender, income, death of a loved one in the past year, lifestyle,
satisfaction with living environment and self-reported comorbidity predicted total frailty,
while each frailty domain was associated with a different set of determinants. The
number of daily-consumed drugs was independently associated with physical frailty,
and the consumption of medication for the cardiovascular system and for the blood
and blood-forming organs explained part of the variance of total and physical frailty.
The adverse effects of polymedication and its direct link with the level of comorbidities
could explain the independent contribution of the amount of prescribed drugs to
frailty prediction. On the other hand, findings in regard to medication type provide
further evidence of the association of frailty with cardiovascular risk. In the present
study, a significant part of frailty was predicted, and the different contributions of each
determinant to frailty domains highlight the relevance of the integral model of frailty. The
added value of a simple assessment of medication was considerable, and it should be
taken into account for effective identification of frailty.
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Introduction
As age increases, physiological reserves inevitably decrease in multiple systems, and comorbidities
become more prevalent (WHO, 1999). Nonetheless, chronological age is not a precise indicator of
functional decline (Bergman et al., 2007). The changes that accompany aging depend on genetic
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and environmental factors, and are lifestyle and life event related
(WHO, 1999). Therefore, while some may remain healthy and
resilient in later life, others may become increasingly vulnerable
to internal and external stressors. The latter refers to a state of
frailty.
Frail individuals are at greater risk of clinically significant
adverse outcomes such as hospitalization, institutionalization
and mortality (Fried et al., 2004, 2009; Abellan van Kan et al.,
2008). Although frailty is generally considered a clinical syn-
drome separate from the normal aging process, there are different
perspectives about its definition (Hogan et al., 2003; Markle-
Reid and Browne, 2003; Bergman et al., 2007; Sternberg et al.,
2011). More traditional approaches to the concept describe frailty
as an exclusively physical condition (presence of three or more
of the following components: weight loss, low physical activ-
ity, exhaustion, slowed performance, and weakness; Fried et al.,
2001), or as a result of the accumulation of multidimensional
deficits (e.g., disabilities, symptoms, signs, diseases; Rockwood
and Mitnitski, 2007). On the other hand, following the more
current trends of frailty definition, the recently described inte-
gral conceptual model specified frailty as a dynamic pre-disability
state that includes losses in physical, psychological and/or social
domains (Gobbens et al., 2010a,b,c).
A broader definition of frailty also involves that the factors
considered as underlying a state of increased vulnerability are
beyond the decline of physiological reserve and comorbidity.
In fact, according to the integral conceptual model of frailty,
life course determinants such as sociodemographic characteris-
tics and lifestyle, life event and environment-related factors can
directly influence frailty, besides influencing the onset of diseases
which can also lead to frailty (Gobbens et al., 2010c,d, 2012).
From this standpoint, as multiple circumstances may impact
the onset of frailty in older persons, researchers should focus
on ascertaining which elements are associated with frailty in
different contexts.
This study’s main objective was to analyze which determi-
nants – described in the integral conceptual model of frailty –
contribute to the prediction of frailty in general and of each
frailty domain (physical, psychological, and social), in a sample
of Portuguese community-dwelling individuals aged 65 years and
over. Furthermore, the present study examined if a simple and
objective measurement, such as assessing the number of daily-
consumed medications, could help to explain frailty variance,
after controlling for the effect of the determinants. It is hypoth-
esized that a higher medication consumption is independently
associated with increased frailty levels. In this context, the inde-
pendent contribution of each type of daily-consumed drugs was
also studied.
Materials and Methods
Study Design and Participants
A cross-sectional study was conducted with a non-probabilistic
sample of 252 community-dwelling elderly (aged 65 years and
over), in three northern Portuguese cities (Maia, Porto, and Vila
Nova de Gaia).
Exclusion criteria were severe cognitive impairment (accord-
ing to guidelines of the National Institute for Health and
Care Excellence (NICE, 2011), participants with Mini Mental
State Examination (Folstein et al., 1975) scores below 10 were
excluded) and being unable to speak Portuguese.
Participants were interviewed in 16 local community institu-
tions, such as social, recreation and day care centers, as well as
senior universities. Trained researchers conducted the interviews
from May to September 2013, using structured questionnaires.
The study was approved by institutional review boards and by
the ethics committee of the Ph.D. in Gerontology and Geriatrics
(Institute of Biomedical Sciences Abel Salazar – University of
Porto). All the participants gave their written informed consent
before the interview.
Measurements
Frailty and determinants of frailty were assessed with the Tilburg
Frailty Indicator (TFI; Gobbens et al., 2010e), which is an oper-
ationalization of the integral conceptual model of frailty. This
brief self-report questionnaire comprises two subscales (parts A
and B). Part A is composed of 10 questions about determinants
of frailty: sociodemographic characteristics (age, sex, marital sta-
tus, nationality, level of education, and income); life events in the
last year (death of a loved one, serious illness, serious illness in
a loved one, divorce or end of an important relationship, traffic
accident, and crime); assessment of how healthy the respon-
dent’s lifestyle is; satisfaction with home living environment; and
the presence of two or more chronic diseases. Part B measures
frailty in three domains: physical (physical health, unexplained
weight loss, difficulty in walking, difficulty in maintaining bal-
ance, hearing problems, vision problems, lack of strength in
hands, and physical tiredness), psychological (cognition, depres-
sion and anxiety symptoms, and coping), and social (living alone,
social relations and support). All items are rated dichotomously
(0–1), with higher scores meaning higher frailty. Scores for each
frailty domain and a total frailty score (0–15) are produced.
The Portuguese version of TFI (Coelho et al., 2014) was used.
This tool has a good internal consistency (KR-20 = 0.78) and
test–retest reliability (r = 0.91) for total frailty score, and there
is encouraging evidence regarding its construct and criterion
validity (Coelho et al., 2014).
Medication was assessed in terms of the type and number
of different daily-consumed drugs. In order to prevent recall
bias, participants were previously asked to bring their medica-
tion or prescriptions to the interview. Based on the guidelines
for ATC classification and DDD assignment (WHO, 2014), the
following groups of medication were considered: cardiovascular
system [e.g., diuretics and angiotensin-converting-enzyme (ACE)
inhibitors], nervous system (e.g., psycholeptics and analgesics),
metabolism (e.g., antidiabetics and mineral supplements), mus-
culoskeletal system (e.g., anti-inflammatories and antirheumat-
ics), digestive system (e.g., antacids and laxatives), blood and
blood forming organs (e.g., antiplatelets and anticoagulants), res-
piratory system (e.g., bronchodilators and antihistamines), geni-
tourinary system (e.g., antispasmodics and medicines for benign
prostatic hyperplasia), endocrine system (e.g., corticosteroids and
Frontiers in Aging Neuroscience | www.frontiersin.org 2 April 2015 | Volume 7 | Article 56
Coelho et al. Frailty predicted by determinants and medication
drugs for thyroid-related diseases), and other clinical conditions
(e.g., infections and diseases of the sensory system).
Finally, measures of cognitive [MMSE (Folstein et al., 1975)],
functional [Barthel Index (Mahoney and Barthel, 1965)/Lawton
and Brody Scale (Lawton and Brody, 1969)] and nutritional status
[Body Mass Index (BMI)] were used for the descriptive analysis
of the sample.
Statistical Analysis
Descriptive statistical analysis was performed using proportions
and measures of central tendency and dispersion, according to
the nature of the variables.
Linear regressions were conducted to ascertain how each
determinant predicts frailty total score and scores per domain.
Hierarchical multiple regression analysis were also performed,
consisting mainly of five steps: in the first one, sociodemo-
graphic characteristics and life events were entered as predictors;
second, assessment of lifestyle and satisfaction with living envi-
ronment; third, self-reported comorbidity; fourth, number of
daily-consumed drugs; and fifth, types of medication. In a sec-
ondary analysis, the MMSE score was inserted in a sixth step, in
order to control for cognitive status.
As in previous studies (Gobbens et al., 2010d, 2012), life event
“serious illness in the last year” was excluded from the analy-
sis because it overlaps with comorbidity. Likewise, marital status
was not considered for the prediction of total frailty and social
frailty because it is closely linked with the TFI item “living alone.”
Variables that revealed low frequencies (<5%) in the descriptive
analysis were excluded in the regression models.
Two-tailed tests were used throughout all analyses and a
p-value < 0.05 was considered statistically significant. All statisti-
cal analyses were performed with IBM SPSS Statistics 22.0 (SPSS,
Inc., Chicago, IL, USA).
Results
Descriptive Analysis
The mean age of the participants was 79.2 years (±7.3), and they
were mostly women (75.8%), widowed (55.6%), and with low
education level (63.9%). The most common monthly household
income was 251–500 euros (32.9%). The most shared life event
(28.2%) was “serious illness in a loved one,” most described their
lifestyle as healthy (54.4%), and were satisfied with their home liv-
ing environment (79.0%). The majority of these elderly reported
the presence of two or more chronic illnesses (53.2%), and the
mean number of different daily-consumed medications was 5.3
(±3.1). The most frequent medications in this sample have been
prescribed for the cardiovascular system (78.6%), nervous sys-
tem (59.9%) and blood and blood forming organs (40.9%). The
mean frailty total score was 6.0 (±3.4), and 2.9 (±2.2), 1.7 (±1.1),
and 1.4 (±1.0) for the physical, psychological and social domains
respectively. The meanMMSE score was 23.6 (±4.9), and regard-
ing the Barthel Index and the Lawton and Brody Scale, the mean
scores were 19.0 (±1.5) and 17.5 (±5.6), respectively. Finally, the
mean BMI of the participants was 28.6 (±5.4). Table 1 provides a
more detailed description of the participants’ characteristics.
TABLE 1 | Characteristics of the participants (n = 252) in regard to
Determinants of frailty, frailty, medication.
Characteristics n (%)
Determinants of frailty (TFI part A)
Age (years), mean ± SD 79.2 ± 7.3
65–74 68 (27.0)
75–84 116 (46.0)
≥85 68 (27.0)
Sex (women) 191 (75.8)
Nationality (Portuguese) 251 (99.6)
Marital status
Married/living with partner 49 (19.4)
Unmarried 24 (9.5)
Separated/divorced 39 (15.5)
Widow/widower 140 (55.6)
Education (years), mean ± SD 4.4 ± 3.6
0 36 (14.3)
1–4 161 (63.9)
≥5 55 (21.9)
Monthly household income (euros)
≤250 20 (7.9)
251–500 83 (32.9)
501–750 50 (19.8)
751–1000 44 (17.5)
1001–1500 25 (9.9)
1501–2000 22 (8.7)
≥2001 8 (3.2)
Life events
Death of a loved one 55 (21.8)
Serious illness 56 (22.2)
Serious illness in a loved one 71 (28.2)
End of important relationship 8 (3.2)
Traffic accident 1 (0.4)
Crime 14 (5.6)
Lifestyle self-assessment
Healthy 137 (54.4)
Not healthy, not unhealthy 92 (36.5)
Unhealthy 23 (9.1)
Satisfaction with living environment 199 (79.0)
Self-reported comorbidity 134 (53.2)
Frailty (TFI part B)
TFI total score (0–15), mean ± SD 6.0 ± 3.4
TFI physical domain score (0–8), mean ± SD 2.9 ± 2.2
TFI psychological domain score (0–4), mean ± SD 1.7 ± 1.1
TFI social domain score (0–3), mean ± SD 1.4 ± 1.0
Medication
Number of daily-consumed medication, mean ± SD 5.3 ± 3.1
Types of daily-consumed medication
Cardiovascular system 198 (78.6)
Nervous system 151 (59.9)
Metabolism 74 (29.4)
Musculoskeletal system 60 (23.8)
Digestive system 93 (36.9)
Blood and blood forming organs 103 (40.9)
Respiratory system 29 (11.5)
(Continued)
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TABLE 1 | Continued
Characteristics n (%)
Genitourinary system 19 (7.5)
Endocrine system 20 (7.9)
Other 23 (9.1)
Cognitive status
MMSE (0–30), mean ± SD 23.6 ± 4.9
Functional status
Barthel Index (0–20), mean ± SD 19.0 ± 1.5
Lawton and Brody Scale (0–23), mean ± SD 17.5 ± 5.6
Nutritional status
BMI (kg/m2 ), mean ± SD 28.6 ± 5.4
Regression Analysis
First, due to the low percentage of non-Portuguese individuals,
nationality was excluded from the regression analysis. Likewise,
life events “divorce or end of important relationship” and “traf-
fic accident” were left out due to the same reason. Also resulting
from the descriptive analysis, the last two categories of income
“1501–2000” and “≥2001” were regrouped in the single category
“≥1501” before inclusion in the regression models. A dummy
variable “cohabit” (“1” for married/living with partner and “0”
for unmarried, separated/divorced and widow/widower) was cre-
ated as an alternative to marital status. A dummy variable for sex
was also created (“1” for women and “0” for men), and lifestyle
was rated “1” for “healthy,” “2” for “not healthy, not unhealthy,”
and “3” for “Unhealthy.” Preliminary analysis showed that the
effects of education, income and lifestyle were linear, whereas the
effects of age were both linear and quadratic. Consequently, age
was squared and centered to allow the analysis of both effects on
the regression models.
Table 2 presents the effects of the determinants on TFI total
score and their significance in the four steps of the hierarchical
regression. The first one showed that age had a quadratic effect
on frailty, with the youngest and oldest participants having less
frailty. Womenwere, on average, frailer thanmen, as well as those
who experienced the death of a loved one in the last year. On the
other hand, as monthly income increases, frailty levels decrease.
Education and life events “serious illness in a loved one” and
“crime” had no effect on frailty. A total of 17.2% of frailty was
predicted in the first step. In the second step, an additional 22.9%
was predicted. Unhealthy lifestyle and dissatisfaction with liv-
ing environment were associated with higher frailty. By including
self-reported comorbidity in the third step, 5.9% of the variance
of frailty was further predicted, with the presence of comorbid-
ity being associated with a higher degree of frailty. By adding
the amount of daily-consumed medication, an additional 2.5%
of frailty was predicted, while the effect of age on frailty was no
longer significant. As hypothesized, a higher number of medi-
cations was associated with higher frailty levels. However, after
including the types of drugs in the regression model, the inde-
pendent effect of the number of daily-consumed drugs on total
frailty was no longer significant. In this last step, an additional
4.2% of frailty was predicted, with significant contributions of the
variables concerning medications for the cardiovascular system
and for the blood and blood forming organs. Frailty was lower
in the participants that consumed drugs such as diuretics and
ACE inhibitors, and higher for those who consumed drugs such
as antiplatelets and anticoagulants.
In regard to physical frailty, a total of 51.3% of TFI physi-
cal domain score was predicted (step 1: R2 = 14.2%; step 2:
R2 = 19.7%; step 3: R2 = 5.9%; step 4: R2 = 5.3%; step
5: R2 = 6.2%). In the last model, physical frailty was asso-
ciated with age (positive linear effect), death of a loved one
in the last year, unhealthy lifestyle, dissatisfaction with living
environment, self-reported comorbidity, higher amount of med-
ications and, likewise to total frailty, non-consumption of drugs
for the cardiovascular system and consumption of drugs for the
blood and blood forming organs. The quadratic effect of age was
no longer significant after adding lifestyle and satisfaction with
living environment, whereas sex and education no longer con-
tributed to physical frailty prediction after adding self-reported
comorbidity. Income, serious illness in a loved one, crime, cohab-
itation and other types of medication had no effect on physical
frailty.
Psychological frailty was significantly higher in women, in par-
ticipants who had experienced the death of a loved one in the
last year, had an unhealthy lifestyle, weren’t satisfied with living
environment and reported comorbidity. The effect of education
was only significant in the first step, whereas the contribution
of age, income, cohabitation, the remainder life events and the
number and type of medications was non-significant throughout
all the steps. A total of 25.3% of TFI psychological domain was
predicted in the first three models (step 1: R2 = 10.8%; step 2:
R2 = 11.9%; step 3: R2 = 2.6%).
Likewise, the variables concerning daily-consumed medi-
cation did not contribute to the prediction of social frailty.
Remarkably, neither did self-reported comorbidity. A total of
27.7% was predicted in the first two steps (step 1: R2 = 19.3%;
step 2: R2 = 8.4%). Social frailty was associated with
age (quadratic effect), being female, higher levels of edu-
cation, lower income, lifestyle and satisfaction with living
environment.
Finally, the effect of the MMSE score on frailty in general
and each frailty domain was non-significant, and its inclusion
in the regression models (in a sixth step) did not influence the
previously observed relationships between variables.
Discussion
A significant proportion of frailty was predicted by life course
determinants and by comorbidity. It was also possible to ascertain
that each determinant played a different role in the prediction
of frailty in general and in each frailty domain. This provides
robust evidence to support the integral conceptual model of
frailty (Gobbens et al., 2010c). On the other hand, the num-
ber of daily-consumed drugs was independently associated with
physical frailty, and the consumption of medication for the car-
diovascular system (e.g., antihypertensives) and for the blood and
blood-forming organs (e.g., antithrombotics) explained part of
the variance of total and physical frailty.
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The observed effect of age on frailty was complex. As in other
studies (Avila-Funes et al., 2008; Gobbens et al., 2010d; Collard
et al., 2012), physical frailty was associated with increased age.
This result was expected considering the physical toll of aging
(Fried et al., 2009). However, total frailty was highest in par-
ticipants aged between 75 and 84 years old, mainly because of
the higher social frailty observed in this group. In fact, most
of the participants who lived alone were included in this age
group, possibly due to the fact that most of the younger par-
ticipants still lived with their spouses, and that many older and
widowed individuals lived with younger family members in order
to receive the support needed to overcome their physical impair-
ments. Nonetheless, the fact that age was no longer significant in
frailty prediction after adding medication to the regression anal-
ysis, indicates that other determinants, including comorbidity,
better explain the variance of frailty.
Similarly to previous research (Puts et al., 2005; Song et al.,
2010; Collard et al., 2012), women were frailer than men. It has
been shown that elderly men have a greater likelihood of dying
suddenly, while women more often show a steady progressive
decline, associated with an increase in morbidity (Puts et al.,
2005). This fact can explain the present findings, including why
the initial sex-based difference in physical frailty has disappeared
after controlling for comorbidity.
As expected (Fried et al., 2001; Woo et al., 2005; Avila-
Funes et al., 2008), frailty was also associated with lower income.
On the other hand, education had a remarkably positive linear
effect on the social frailty domain. This result was surprising
considering that in previous research the association of edu-
cation with frailty was either non-significant (Gobbens et al.,
2010d; Garcia-Garcia et al., 2011), or negative (Fried et al., 2001;
Woo et al., 2005; Barreto Pde et al., 2012), with lower educa-
tion levels predicting higher frailty. The present finding may be
explained by different views and expectations of social support
and relationship quality, from individuals with distinct education
levels.
Death of a loved one was the only life event associated with
frailty. Considering the well-documented physical and psycho-
logical impact of bereavement (Stroebe et al., 2007), it is under-
standable that this event could lead to frailty. Concomitantly,
unhealthier lifestyle and dissatisfaction with living environment
predicted frailty in general and in each domain. This provides fur-
ther evidence of the previously described importance of health-
related behavior (Avila-Funes et al., 2008; Fried et al., 2009;
Gobbens et al., 2010d) and environmental factors (Hogan et al.,
2003; Markle-Reid and Browne, 2003; Bergman et al., 2007) in
precipitating frailty.
Self-reported comorbidity, as in previous research (Gobbens
et al., 2010d), predicted frailty in general, as well as physical and
psychological frailty. Most authors agree that comorbidity can
lead to the onset of frailty (Bergman et al., 2007; Fried et al.,
2009; Morley et al., 2013). Nonetheless, as described in other
studies (Kriegsman et al., 1996), assessing comorbidity trough
self-report may be susceptible to bias, mainly because of its
dependence on the participants’ insight regarding chronic dis-
ease. Consequently, as it is directly linked with the amount of
comorbidities, the number of daily-consumed drugs might have
been a more precise indicator of the participants’ health sta-
tus. Moreover, considering that self-reported comorbidity was
rated dichotomously (yes/no), the assessment of the amount of
consumed drugs not only is more accurate, but also allows a
broader characterization of the heterogeneity of the participants’
comorbidity burden.
In fact, as hypothesized, the assessment of medication allowed
the prediction of an additional variance of frailty, mainly because
of the higher physical frailty of individuals who take greater
amounts of medication. It can be discussed that assessing med-
ication, a less subjective measure than self-reported comorbid-
ity, was associated with the less subjective domain of frailty.
Nonetheless, one should consider that these findings may also
be linked with the adverse outcomes of polymedication and its
association with frailty (Gnjidic et al., 2012a,b).
Frailty in general and physical frailty were also predicted
by the consumption of medication for the cardiovascular sys-
tem and for the blood and blood-forming organs. Considering
that the latter medication type includes the antiplatelet drugs,
which are the mainstay of cardiovascular disease prevention (Lin
et al., 2010; Renda and de Caterina, 2012), it is possible to con-
clude that frailty was independently associated with the usage of
drugs that target cardiovascular risk. Indeed, previous research
(Fried et al., 2001; Afilalo et al., 2009; Solfrizzi et al., 2013) has
shown that frailty – particularly physical frailty – may be asso-
ciated with common cardiovascular diseases and with their own
determinants.
Frailty was lower for those medicated for the cardiovascular
system and higher for those who consumed antiplatelet drugs.
Although there is limited evidence in this regard, one could
argue that the drugs included in the first group were effective
in minimizing cardiovascular risk factors and, therefore led to
the prevention or to the decrease of frailty (Strandberg and
Pitkala, 2007; Afilalo et al., 2009). Moreover, there are studies
that suggest that ACE inhibitors improve physical function in
elderly individuals, particularly regarding frailty related compo-
nents, such as mobility and muscle strength (Hutcheon et al.,
2002; Onder et al., 2002; Sumukadas et al., 2007). On the other
hand, the results regarding the increased frailty of the partic-
ipants who consumed antiplatelet drugs may be explained by
the likely higher cardiovascular risk of these individuals. In fact,
according to European Guidelines on Cardiovascular Disease
Prevention in Clinical Practice (Perk et al., 2012), antiplatelet
therapy, particularly low-dose of acetylsalicylic acid, should be
prescribed to hypertensive patients with a history of cardiovas-
cular events, with reduced renal function or with high cardio-
vascular risk. Furthermore, previous research (Burgess et al.,
2007) has shown that the consumption of antithrombotics is
associated with history of atrial fibrillation and stroke, which
in turn can lead to frailty (Woods et al., 2005; Afilalo et al.,
2009).
The main strengths of the present study are the statisti-
cal procedures used, the reinforcement of the current evidence
supporting the multidimensional nature of frailty and of its pre-
dictors, and the findings regarding an ameliorated prediction
of frailty based on an objective, easy to execute, assessment of
medication. It is also the first study that analyzes the determinants
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considered in the integral conceptual model of frailty in elderly
individuals from a southern European country. Some limitations
of this study should be also noted. First, the non-probabilistic
sampling method could have limited these findings namely in
regard to their generalization. Moreover, in the present study,
the proportion of women (75.8%) is considerably larger than
the proportion of men. However, this difference roughly reflects
the current sociodemographic characteristics of the Portuguese
elderly population, in which there is an increasingly larger pro-
portion of women in older age groups (INE, 2012). On the other
hand, correlation coefficient values were somewhat low, probably
due to the small sample size. Also, the cross-sectional design does
not allow the examination of the temporal continuum between
determinants, comorbidity, consumed medications and frailty, in
order to conclude causality. In turn, the definition of broad med-
ication types/groups could have limited the results. For example,
the inclusion of antidiabetics as well as vitamins and mineral
supplements in the same group could have limited the ability
of this medication type to explain frailty variance. Taking this
into consideration, as elderly individuals with diabetes tend to
have a greater risk of becoming frail (Fried et al., 2001; Woods
et al., 2005), an association would be expected if only antidiabet-
ics were considered. Finally, the self-report nature of TFI can be
considered a limitation because of its inherent subjectivity and
reliance on memory and insight (Farias et al., 2005; Frank et al.,
2011; Antoine et al., 2013). Nonetheless, TFI items correlated
as expected with corresponding standardized measures in previ-
ous research (Gobbens et al., 2010e; Coelho et al., 2014) and, in
the present study, the relationship between self-reported deter-
minants and frailty was not significantly influenced by cognitive
status.
Several directions for future research can be suggested.
Longitudinal studies should be conducted to better examine how
life course determinants and comorbidity predict frailty in the
short, medium, and long term. Also, further studies should focus
on the association of comorbidity and medications with the psy-
chological and social domains of frailty. Likewise, the association
between level of education and each frailty domain should be
thoroughly analyzed, especially considering the findings of this
study in regard to social frailty.
Conclusion
This research provides important data about which factors may
precipitate states of higher vulnerability in this elderly sample.
Furthermore, the added value of a brief assessment of medication
was significant, so it should be considered as supplementary to
TFI. These findings should be taken into account for a more effec-
tive identification of frailty, and to implement timely and targeted
interventions in order to treat this syndrome and prevent related
adverse outcomes.
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